This is a working overview of visceral adipose tissue, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
| Property | Value | Notes |
|---|---|---|
| Drug class | Peptide hormone analog | Acts at the growth hormone-releasing hormone receptor |
| Receptor | Growth hormone-releasing hormone receptor | G protein-coupled; raises cyclic AMP in somatotrophs |
| Key mediator | Insulin-like growth factor 1 | Increases with repeated administration |
| Main studied population | Adults with HIV-associated lipodystrophy | Trials measured visceral adipose tissue by imaging |
| Route | Subcutaneous injection | Given once daily in clinical use |
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
=== Retinopathy of prematurity === Clinical work is at an earlier stage in the development of Iplex to treat Retinopathy of Prematurity (ROP). This disease, affecting an estimated 14,000 to 16,000 premature infants each year, causes the lack of development of the small blood vessels in the back of the eye leading to blindness in the majority of cases. A Phase I clinical study investigating Iplex as a treatment for ROP has been initiated at the University of Gothenburg in Sweden, in collaboration with scientists at the Harvard Medical School in the U.S. results of this study are expected by the end of 2007.
interphase All stages of the cell cycle excluding cell division. A typical cell spends most of its life in interphase, during which it conducts everyday metabolic activities as well as the complete replication of its genome in preparation for mitosis or meiosis.
== Application in biotechnology == In some of the aminoacyl tRNA synthetases, the cavity that holds the amino acid can be mutated and modified to carry unnatural amino acids synthesized in the lab, and to attach them to specific tRNAs. This expands the genetic code, beyond the twenty canonical amino acids found in nature, to include an unnatural amino acid as well. The unnatural amino acid is coded by a nonsense (TAG, TGA, TAA) triplet, a quadruplet codon, or in some cases a redundant rare codon. The organism that expresses the mutant synthetase can then be genetically programmed to incorporate the unnatural amino acid into any desired position in any protein of interest, allowing biochemists or structural biologists to probe or change the protein's function. For instance, one can start with the gene for a protein that binds a certain sequence of DNA, and, by directing an unnatural amino acid with a reactive side-chain into the binding site, create a new protein that cuts the DNA at the target-sequence, rather than binding it. By mutating aminoacyl tRNA synthetases, chemists have expanded the genetic codes of various organisms to include lab-synthesized amino acids with all kinds of useful properties: photoreactive, metal-chelating, xenon-chelating, crosslinking, spin-resonant, fluorescent, biotinylated, and redox-active amino acids. Another use is introducing amino acids bearing reactive functional groups for chemically modifying the target protein.
. For electrical circuits, let n be the concentration of free charged particles (in m−3) and let q* be the charge of each particle (in coulombs). (For electrons, q* = e = 1.6×10−19 C.) Then nQ is the number of particles in the volume Q, and nQq* is their total charge. This is the charge that flows through the cross section per unit time, i.e. the current I. Therefore, I = nQq*. Consequently, Q = I/nq*, and
Sources: en.wikipedia.org
The osmotic-controlled release oral delivery system (OROS) is an advanced controlled release oral drug delivery system in the form of a rigid tablet with a semi-permeable outer membrane and one or more small laser drilled holes in it. As the tablet passes through the body, water is absorbed through the semipermeable membrane via osmosis, and the resulting osmotic pressure is used to push the active drug through the laser drilled opening(s) in the tablet and into the gastrointestinal tract. OROS is a trademarked name owned by ALZA Corporation, which pioneered the use of osmotic pumps for oral drug delivery.
In his memoir I'm Not the Only One (2004), Galloway wrote:"Just as Stalin industrialised the Soviet Union, so on a different scale Saddam plotted Iraq's own Great Leap Forward. ... He managed to keep his country together until 1991. Indeed, he is likely to have been the leader in history who came closest to creating a truly Iraqi national identity, and he developed Iraq and the living, health, social and education standards of his own people." In the book, Galloway also expressed the opinion that Kuwait, which Iraq invaded, is "clearly a part of the greater Iraqi whole, stolen from the motherland by perfidious Albion". Christopher Hitchens responded that the state existed before Iraq had a name. The massacres of Kurds and Shias after the 1991 Gulf War, was according to Galloway, "a civil war that involved massive violence on both sides". In 2006 a video surfaced showing Galloway greeting Uday Hussein, Saddam's eldest son, with the title of "Excellency", at Uday's palace in 1999. Galloway is heard saying he will be with Uday "until the end". Galloway continued to praise Iraq's prime minister under Saddam, Tariq Aziz. In April 2005, on Al Jazeera during that year's general election campaign, he described Aziz as "an eminent diplomatic and intellectual person". In his opinion, Aziz was "a political prisoner" and advocated his release.
== Weaknesses == The assay is limited to using existing restriction sites in the region of interest, and methylation that does not occur in the context of a specific restriction site will not be assayed. Incomplete digestion by restriction enzymes after PCR can confound the analysis: incomplete digestion would suggest lack of DNA methylation (if cutting with a methylation-sensitive enzyme such as HpaII). It is also known that BstUI can cut at unconverted sites, leading to overestimation of methylation levels and so the use of HpaII is often needed. In complex samples, cell-type heterogeneity can confound the analysis since the DNA is not being sequenced, heterogeneity in sequences from different cells in the sample (i.e. different cell populations within a tumor) that have acquired mutations in the interrogated region, such as changing the CG dinucleotide to CA or CT, would result in loss of the restriction site giving rise to an apparently methylated region due to lack of digestion. This would skew the quantification of DNA methylation levels in a given sample.
It was taken to and put on display in Melbourne Zoo, but died on 12 September 1950. Taipan antivenom became available by mid-1955, and it was used for the first time on 10-year-old Bruce Stringer, who had been bitten at his school south of Cairns. As well as describing the Papuan taipan, Slater was instrumental in capturing and milking taipans both in New Guinea and Australia. In Bereina west of Port Moresby in 1957, Slater encountered a pair of taipans mating and bagged them, but was bitten by the male in the process. He managed to insert a syringe into a vein in his left ankle and give himself taipan antivenom. Despite this, he sickened and spent 10 days in hospital. Slater was the only person milking snakes for the PNG Department of Agriculture. After he resigned in 1959, the department announced they would pay £8/foot for each Papuan taipan caught; which equates to approximately $300 AUD/foot as of 2024. Dismayed, Slater feared that unskilled people would be emboldened to try to catch them; one person was reported to have died this way during this period. Coastal taipans were responsible for 4% (31 cases) of identified snakebite victims in Australia between 2005 and 2015, though no deaths were recorded in this cohort. At least one death from this species was recorded in a coronial retrospective study of snakebites from 2000 to 2016, and two between 1981 and 1991. Bites from the coastal taipan account for most snakebites in New Guinea in the rainy season, when the snake becomes more active, particularly in southern parts of the island.
Norway had rejected joining in a 1972 referendum, while the UK confirmed its membership in a 1975 referendum. Aside from the European Economic Community itself, the European continent underwent a profound transition towards democracy. The dictators of Greece and Portugal were deposed in 1974, and Spain's dictator died in 1975, enabling their accession in 1981 and 1986. In 1979, the European Parliament had its first direct elections, reflecting a growing consensus that the EEC should be less a union of member states, and more a union of peoples. The 1986 Single European Act increased the number of treaty issues in which qualified majority voting (rather than consensus) would be used to legislate, as a way to accelerate trade integration. The Schengen Agreement of 1985 (not initially signed by Italy, the UK, Ireland, Denmark or Greece) allowed movement of people without any border checks. Meanwhile, in 1987, the Soviet Union's Mikhail Gorbachev announced policies of "transparency" and "restructuring" (glasnost and perestroika). This revealed the depths of corruption and waste. In April 1989, the People's Republic of Poland legalised the Solidarity organisation, which captured 99% of available parliamentary seats in June elections. These elections, in which anti-communist candidates won a striking victory, inaugurated a series of peaceful anti-communist revolutions in Central and Eastern Europe that eventually culminated in the fall of communism.
Sources: en.wikipedia.org
==== Phosphate reduction ==== A key goal in the management of chronic kidney disease in cats is to reduce dietary phosphate intake early in the course of the disease. As a rule of thumb, the phosphate content can be reduced to 170 mg/MJ UE (Megajoule metabolizable energy, see also Physiological calorific value), i.e. to two thirds of the maintenance requirement. Commercially available cat food usually contains twice the maintenance requirement and should therefore not be mixed with the diet food. If the phosphate levels in the plasma remain elevated despite the renal diet, absorption in the intestine can be reduced by using calcium salts and phosphate binders such as aluminum hydroxide, aluminum carbonate or lanthanum carbonate. Calcium carbonate can compensate for calcium deficiency in the early stages, but can lead to hypercalcemia in advanced stages. The use of phosphate binders should be monitored by blood tests and their dose adjusted on the basis of phosphate levels. Several studies have shown that a reduction of phosphate in the diet is sufficient to slow down the progression of the disease. If the general condition continues to deteriorate during phosphate reduction, a phosphate deficiency should also be considered. This manifests itself in a similar way to chronic kidney disease: shaggy coat, loss of appetite, weakness, exhaustion and anaemia. Calcitriol can also be used to treat secondary hyperparathyroidism, but only if parathyroid hormone and calcium levels are monitored.
Protein sequences contain sequence motifs that are recognized by modifying enzymes, and which can be documented or predicted in PTM databases. With the large number of different modifications being discovered, there is a need to document this sort of information in databases. PTM information can be collected through experimental means or predicted from high-quality, manually curated data. Numerous databases have been created, often with a focus on certain taxonomic groups (e.g. human proteins) or other features.
==== Elimination ==== Muscimol is excreted by the kidneys into urine. It is excreted partially unmetabolized. This has been taken advantage of by Siberian practitioners of the traditional entheogenic use of Amanita muscaria via recycling of muscimol in urine. The elimination half-life of muscimol in humans is unknown. The closely related drug gaboxadol (THIP), which is a cyclized derivative of muscimol, has an elimination half-life in humans of 1.5 to 2 hours. In rodents, the half-life of gaboxadol was about twice as long as that of muscimol. Gaboxadol is said to be more resistant to metabolism than muscimol, for instance not being a substrate for GABA-T. Despite the preceding findings however, gaboxadol is shorter-lasting in its effects than muscimol in rats, with durations of up to 3 hours and more than 5 hours, respectively.
=== 26 April === Yevgeny Roizman, former mayor of Yekaterinburg and opposition politician, went on trial for discrediting the Russian army over the war in Ukraine. He pled not guilty to the charge, which carries a five-year jail term. President of Ukraine Volodymyr Zelenskyy held the first phone call with Xi Jinping since the beginning of the Russian invasion of Ukraine. After the call, Zelenskyy appointed a new ambassador to China, Pavlo Riabikin. Xi Jinping pledged to send a peace talks delegation to Ukraine.
A common natural contaminant, DS is present at levels of 1–7% in heparin API but has no proven biological activity that influences the anticoagulation effect of heparin. In December 2007, the US Food and Drug Administration (FDA) recalled a shipment of heparin because of bacterial growth (Serratia marcescens) in several unopened syringes of this product. S. marcescens can lead to life-threatening injuries and/or death.
Sources: en.wikipedia.org
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.
Administered growth hormone supplies the hormone directly, while this peptide acts upstream by prompting the pituitary to release it. The indirect route preserves pulsatile secretion and some endogenous feedback, which changes the hormone and IGF-1 profile observed after treatment.
Reductions in visceral adipose tissue appear consistently in randomized trials of the approved population. Effects on peripheral fat, cardiovascular outcomes, and use outside that population are less well established.
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.